Achillion Pharmaceuticals Inc ACHN:NASDAQ (Common Stock)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 10.73 | 0.97 9.94% | 4,800 | 4.9M |
Latest News Headlines for Achillion Pharmaceuticals Inc
Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
CHICAGO, Sept. 30, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACHN, DWA, SUNE, LOCO and WFM. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Latest Annual and Quarterly SEC Filings
More FilingsCompany Background
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.
collapse, right-facing arrow indicating collapsed view of sectionOverview
| Bid | Size | -- | -- |
|---|---|
| Ask | Size | -- | -- |
| Price Open | 9.76 |
| Previous Close | 10.73 |
| Day High | -- |
| Day Low | -- |
| 52 Week High | 9/4/2014 | 13.80 |
| 52 Week Low | 10/31/2013 | 2.26 |
| % Off 52 Week High | -22.25% |
| % Off 52 Week Low | 374.78% |
| Beta (5 Yr) | 2.34 |
| Volatility Avg | 10/8/2014 | 118.35 |
| 10-Day Avg. Volume | 4,873,286 |
| Market data is delayed by at least 20 minutes. | |
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
| EPS (TTM) | 6/30/2014 | -0.61 |
|---|---|
| P/E Ratio | 6/30/2014 | -- |
| Market Cap | Small Cap | 1B |
| Shares Outstanding | 97.79M |
| Float | 97.5M |
collapse, right-facing arrow indicating collapsed view of sectionDividends
| Dividend Yield | -- |
|---|---|
| Ex-Date | -- |
| Dividend Announcement | -- |
| Date of Record | -- |
| Payable | -- - -- |
| Payable Date | -- |
Peers Information HelpACHN Achillion Pharmaceuticals Inc vs. Peers
| Peers | |
|---|---|
ACHN Achillion Pharmaceuticals Inc | 223.29% |
Pfizer Inc. | -4.08% |
Johnson & Johnson | 14.54% |
Merck & Co., Inc. | 20.24% |
Abbott Laboratories | 9.94% |
ACHN Achillion Pharmaceuticals Inc | 0.00% |
Pfizer Inc. | 3.54% |
Johnson & Johnson | 2.67% |
Merck & Co., Inc. | 2.92% |
Abbott Laboratories | 2.09% |
ACHN Achillion Pharmaceuticals Inc | 9.94% |
Pfizer Inc. | 2.05% |
Johnson & Johnson | 2.46% |
Merck & Co., Inc. | 2.94% |
Abbott Laboratories | 1.64% |